<b>Background:</b> The advent of first- and second-generation BCR/ABL1 tyrosine kinase inhibitors (TKIs), such as imatinib and dasatinib, has markedly improved the clinical outcomes of patients with philadelphia chromosome-positive acute lymphoblastic leukemia (Ph<sup>+</sup>-ALL). This evidence concerns the gene BCR and acute lymphoblastic leukemia.